{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-25-000039","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.904345+00:00","generated_at":"2026-05-17T03:51:02.766329+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Halozyme issues position statement on CMS final IPAY 2028 Medicare negotiation guidance","bullets":["Statement includes long-term projections of U.S. Medicare Part B spend as % of total ENHANZE partner product SC sales.","No specific financial projections or quantitative details were disclosed in the 8-K or attached exhibit.","The exhibit text provided is only a title; substantive content must be accessed on the company's website."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-25-000039","json":"https://secwatch.observer/filing/0001159036-25-000039.json","markdown":"https://secwatch.observer/filing/0001159036-25-000039.md","text":"https://secwatch.observer/filing/0001159036-25-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000039/0001159036-25-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000039/halo-20251014.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:51:02.766329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}